Genelux (NASDAQ:GNLX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX) from a sell rating to a hold rating in a research report released on Saturday.

Other research analysts have also recently issued reports about the company. Lake Street Capital initiated coverage on Genelux in a research report on Tuesday, October 21st. They set a “buy” rating and a $16.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Loop Capital set a $16.00 price objective on Genelux in a research note on Tuesday, October 21st. Finally, Maxim Group set a $20.00 target price on shares of Genelux in a research note on Tuesday, October 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Genelux Trading Down 23.5%

Genelux stock opened at $3.48 on Friday. Genelux has a 1-year low of $1.99 and a 1-year high of $8.53. The company has a fifty day simple moving average of $5.21 and a 200 day simple moving average of $4.38. The company has a market cap of $132.41 million, a P/E ratio of -3.95 and a beta of 0.17.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. On average, equities research analysts forecast that Genelux will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other Genelux news, Director John Thomas sold 10,000 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $5.00, for a total value of $50,000.00. Following the completion of the sale, the director owned 492,784 shares of the company’s stock, valued at $2,463,920. The trade was a 1.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 15,990 shares of company stock valued at $82,054. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Genelux

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Private Management Group Inc. acquired a new stake in Genelux during the 2nd quarter valued at approximately $33,000. American Century Companies Inc. acquired a new position in Genelux in the first quarter valued at $51,000. Beacon Capital Management LLC boosted its position in Genelux by 99.8% during the second quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock valued at $55,000 after acquiring an additional 9,550 shares during the last quarter. Falcon Wealth Planning grew its holdings in Genelux by 83.3% during the 2nd quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock worth $63,000 after acquiring an additional 10,000 shares during the period. Finally, Raymond James Financial Inc. raised its position in shares of Genelux by 22.6% in the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after acquiring an additional 5,333 shares in the last quarter. 37.33% of the stock is currently owned by institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.